Pulmonary vascular reserve during experimental pulmonary embolism: Effects of a soluble guanylate cyclase stimulator, BAY 41-8543

Critical Care Medicine

Volumn 39, Issue 12, 2011, Pages 2700-2704

  Watts, John A ^a   Gellar, Michael A ^a   Fulkerson, Mary Beth K ^a   Kline, Jeffrey A ^a  

^a CAROLINAS MEDICAL CENTER   (United States)

Author keywords

BAY 41 8543; pulmonary embolism; pulmonary gas exchange; pulmonary hypertension; soluble guanylyl cyclase; vasodilation

Indexed keywords

2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL] 5 MORPHOLINO 4,6 PYRIMIDINEDIAMINE; HEMOGLOBIN; LACTIC ACID; MICROSPHERE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL OXYGEN SATURATION; ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; HEART OUTPUT; HEMOGLOBIN BLOOD LEVEL; HEMOLYSIS; LOW DRUG DOSE; LUNG ARTERY PRESSURE; LUNG EMBOLISM; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT; SYSTOLIC BLOOD PRESSURE; VASODILATATION;

ANIMALS; BLOOD PRESSURE; CARDIAC OUTPUT; DOSE-RESPONSE RELATIONSHIP, DRUG; GUANYLATE CYCLASE; HEMOLYSIS; LUNG; MALE; MORPHOLINES; PULMONARY EMBOLISM; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; VASODILATOR AGENTS;

EID: 81855222099     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e318226678e     Document Type: Article

References (27)

1. Tapson VF: Acute pulmonary embolism. N Engl J Med 2008; 358:1037-1052
2. Smulders YM: Pathophysiology and treatment of haemodynamic instability in acute pulmonary embolism: The pivotal role of pulmonary vasoconstriction. Cardiovasc Res 2000; 48:23-33
3. Stratmann G, Gregory GA: Neurogenic and humoral vasoconstriction in acute pulmonary thromboembolism. Anesth Analg 2003; 97:341-354 (Pubitemid 36899727)
4. Goldhaber SZ, Elliott CG: Acute pulmonary embolism: Part II: Risk stratification, treatment, and prevention. Circulation 2003; 108: 2834-2838 (Pubitemid 37517808)
5. Schoepf UJ, Kucher N, Kipfmueller F, et al: Right ventricular enlargement on chest computed tomography: A predictor of early death in acute pulmonary embolism. Circulation 2004; 110:3276-3280 (Pubitemid 39525077)
6. Kearon C, Kahn SR, Agnelli G, et al: Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (eighth edition). Chest 2008; 133: 454S-545S (Pubitemid 351892971)
7. Watts JA, Zagorski J, Gellar MA, et al: Cardiac inflammation contributes to right ventricular dysfunction following experimental pulmonary embolism in rats. J Mol Cell Cardiol 2006; 41:296-307 (Pubitemid 44080220)
8. Watts JA, Gellar MA, Obraztsova M, et al: Role of inflammation in right ventricular damage and repair following experimental pulmonary embolism in rats. Int J Exp Pathol 2008; 89:389-399
9. Runyon MS, Gellar MA, Sanapareddy N, et al: Development and comparison of a minimally-invasive model of autologous clot pulmonary embolism in Sprague-Dawley and Copenhagen rats. Thromb J 2010; 8:3
10. Jones AE, Watts JA, Debelak JP, et al: Inhibition of prostaglandin synthesis during polystyrene microsphere-induced pulmonary embolism in the rat. Am J Physiol Lung Cell Mol Physiol 2003; 284:L1072-L1081 (Pubitemid 36687144)
11. Breuer J, Meschig R, Breuer HW, et al: Effects of serotonin on the cardiopulmonary circulatory system with and without 5-HT2-receptor blockade by ketanserin. J Cardiovasc Pharmacol 1985; 7:64-66
12. Battistini B: Modulation and roles of the endothelins in the pathophysiology of pulmonary embolism. Can J Physiol Pharmacol 2003; 81:555-569 (Pubitemid 36836391)
13. Evgenov OV, Kohane DS, Bloch KD, et al: Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation. Am J Respir Crit Care Med 2007; 176: 1138-1145 (Pubitemid 350223760)
14. Schermuly RT, Stasch JP, Pullamsetti SS, et al: Expression and function of soluble guan-ylate cyclase in pulmonary arterial hypertension. Eur Respir J 2008; 32:881-891
15. Grimminger F, Weimann G, Frey R, et al: First acute haemodynamic study of soluble guanylate cyclase stimulator Riociguat in pulmonary hypertension. Eur Respir J 2009; 33:785-792
16. Belik J: Riociguat, an oral soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension. Curr Opin Investig Drugs 2009; 10:971-979
17. Kline JA, Marchick MR, Hogg MM: Reduction in plasma haptoglobin in humans with acute pulmonary embolism causing tricuspid regurgitation. J Thromb Haemost 2009; 7:1597-1599
18. Zagorski J, Marchick MR, Kline JA: Rapid clearance of circulating haptoglobin from plasma during acute pulmonary embolism in rats results in HMOX1 up-regulation in peripheral blood leukocytes. J Thromb Haemost 2010; 8:389-396
19. Rother RP, Bell L, Hillmen P, et al: The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: A novel mechanism of human disease. JAMA 2005; 293:1653-1662 (Pubitemid 40471796)
20. Morris SM Jr: Recent advances in arginine metabolism: Roles and regulation of the arginases. Br J Pharmacol 2009; 157:922-930
21. Dias-Junior CA, Gladwin MT, Tanus-Santos JE: Low-dose intravenous nitrite improves hemodynamics in a canine model of acute pulmonary thromboembolism. Free Rad Biol Med 2006; 41:1764-1770 (Pubitemid 44848399)
22. Souza-Silva AR, Dias-Junior CA, Uzuelli JA, et al: Hemodynamic effects of combined sildenafil and L-arginine during acute pulmonary embolism-induced pulmonary hypertension. Eur J Pharmacol 2005; 524: 126-131 (Pubitemid 41606824)
23. Bottiger BW, Motsch J, Dorsam J, et al: Inhaled nitric oxide selectively decreases pulmonary artery pressure and pulmonary vascular resistance following acute massive pulmonary microembolism in piglets. Chest 1996; 110:1041-1047 (Pubitemid 26347624)
24. Tanus-Santos JE, Moreno H Jr, Zappellini A, et al: Small-dose inhaled nitric oxide attenuates hemodynamic changes after pulmonary air embolism in dogs. Anesth Analg 1999; 88:1025-1029 (Pubitemid 29211532)
25. Watts JA, Marchick MR, Gellar MA, et al: Up-regulation of arginase II contributes to pulmonary vascular endothelial cell dysfunction during experimental pulmonary embolism. Pulm Pharmacol Ther 2011; 24: 407-413
26. Evgenov OV, Pacher P, Schmidt PM, et al: NO-independent stimulators and activators of soluble guanylate cyclase: Discovery and therapeutic potential. Nat Rev Drug Discov 2006; 5:755-768 (Pubitemid 44323702)
27. Cau SB, Dias-Junior CA, Montenegro MF, et al: Dose-dependent beneficial hemodynamic effects of BAY 41-2272 in a canine model of acute pulmonary thromboembolism. Eur J Pharmacol 2008; 581:132-137